CD70-targeted immunoPET Imaging of Kidney Cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Processing failed - manual review needed

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Aged 18-80 year-old and of either sex；
2. Histologically confirmed diagnosis of kidney cancer (especially clear cell renal cell carcinoma and papillary renal cell carcinoma) or suspected kidney cancer by diagnostic imaging;
3. Capable of giving signed informed consent, including compliance with the requirements and restrictions listed in the informed consent form (ICF) and this protocol.

Exclusion Criteria:

1. Pregnancy；
2. Severe hepatic and renal insufficiency;
3. History of serious surgery in the last month;
4. Allergic to antibody or single-domain antibody radiopharmaceuticals.

Where it's running

• Renji Hospital, School of Medicine, Shanghai Jiao Tong University
  Shanghai, Shanghai Municipality, China Recruiting

Study contacts

• Principal investigator: Weijun Wei, Ph.D. & M.D. — Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University
• Study coordinator: Weijun Wei, Ph.D. & M.D.
• Email: wwei@shsmu.edu.cn
• Phone: 15000083153

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using vorolanib for treating advanced kidney cancer

  This study is testing if the drug vorolanib can help people with advanced kidney cancer live longer when used as a second treatment option.

  Recruiting Jinling Hospital, China · Nanjing, Jiangsu · NCT06676527

• Methylscape test in body fluids for multi-cancer detection in Colombia

  A simple blood, urine, or saliva test called Methylscape is being tested to see if it can detect multiple cancers and identify where the signal is coming from, using people with cancer and healthy volunteers in Colombia.

  Recruiting Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo · Bogotá, Bogota D.C. · NCT07741435

• Benchmarking AI language models against tumor boards for oncology treatment decisions

  This project tests whether frontier AI language models can match the treatment recommendations of multidisciplinary tumor boards for common cancers using standardized synthetic cases.

  Recruiting Assistance Publique - Hôpitaux de Paris · Boulogne-Billancourt and 4 other locations · NCT07739121

• Using 18F-Fluciclovine PET/CT to Predict Outcomes of Prostate Cancer Therapy

  This study is testing if special imaging can help predict how well a new prostate cancer treatment works for patients with advanced disease.

  Recruiting Phase 4 VA Greater Los Angeles Healthcare System · Los Angeles, California · NCT06706921

• Combination of chemotherapy and immunotherapy for advanced penile cancer

  This study is testing a new treatment combining chemotherapy and immunotherapy for adults with advanced penile cancer to see if it helps them respond better to therapy and manage their disease.

  Recruiting at 2 sites Phase 2 The Netherlands Cancer Institute · Leuven and 1 other locations · NCT06353906

• Evaluating HTL0039732 for Advanced Solid Tumours

  This study is testing a new drug called HTL0039732, alone and with another treatment, to see if it can help people with advanced solid tumors by boosting their immune response against cancer.

  Recruiting at 6 sites Phase 1/2 Cancer Research UK · Cambridge and 5 other locations · NCT05944237

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.